173. Bull Cancer. 2018 Apr;105(4):431-439. doi: 10.1016/j.bulcan.2018.01.013. Epub2018 Mar 19.[Neuroendocrine tumors of the breast: Myth or reality? A systematic review].[Article in French]Cheymol C(1), Abramovici O(2), Do Cao C(3), Dumont A(4), Robin YM(2), El HajbiF(5), Dansin E(6), Bonneterre J(1), Lauridant G(7).Author information: (1)Centre régional de lutte contre le cancer des Hauts de France, centreOscar-Lambret, département de sénologie, 3, rue Frédéric-Combemale, 59000 Lille, France.(2)Centre régional de lutte contre le cancer des Hauts de France, centreOscar-Lambret, département d'anatomie et cytopathologie, 3, rueFrédéric-Combemale, 59000 Lille, France.(3)Centre hospitalo-universitaire régional de Lille 2, service d'endocrinologie, diabétologie et maladies métaboliques, avenue Oscar-Lambret, 59000 Lille, France.(4)Centre régional de lutte contre le cancer des Hauts de France, centreOscar-Lambret, unité d'oncologie moléculaire humaine, 3, rue Frédéric-Combemale, 59000 Lille, France.(5)Centre régional de lutte contre le cancer des Hauts de France, centreOscar-Lambret, département d'oncologie urodigestive, 3, rue Frédéric-Combemale,59000 Lille, France.(6)Centre régional de lutte contre le cancer des Hauts de France, centreOscar-Lambret, département de cancérologie cervicofaciale et thoracique, 3, rueFrédéric-Combemale, 59000 Lille, France.(7)Centre régional de lutte contre le cancer des Hauts de France, centreOscar-Lambret, département de sénologie, 3, rue Frédéric-Combemale, 59000 Lille, France. Electronic address: g-lauridant@o-lambret.fr.Primary neuroendocrine breast carcinomas are rare and little-known tumors. Only alimited number of studies on neuroendocrine breast carcinomas have been reported in the literature, and the vast majority of them are small retrospective seriesor case reports. According to the World Health Organization (WHO), they accountfor only 2 % to 5 % of breast cancers. Their diagnosis relies on the presence of a neuroendocrine architecture and the expression of neuroendocrine markers(chromogranin A and/or synaptophysin). The revised 2012 WHO classificationsubdivides them into three categories: (i) well-differentiated neuroendocrinecarcinomas, (ii) poorly differentiated neuroendocrine carcinomas or small-cellcarcinomas, and (iii) invasive breast carcinomas with neuroendocrinedifferentiation. Their clinical features and radiological characteristics are notdifferent from those of other types of breast cancer. Because of discordantresults, their clinical outcome is still poorly defined. So far, no standardtreatment has been established, and most clinicians draw on their experience ofinvasive ductal cancer. The role of specific treatments like platinum-basedchemotherapy, somatostatin analogues, peptide receptor radionucleide therapy ortemozolomide remains unclear. A better knowledge of the molecular pathwaysinvolved in their carcinogenesis could help to identify new potential therapeutictargets. The efficacy of targeted therapies has to be studied.Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS.All rights reserved.DOI: 10.1016/j.bulcan.2018.01.013 PMID: 29567279  [Indexed for MEDLINE]